Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. cut its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,949 shares of the biopharmaceutical company’s stock after selling 516 shares during the period. E Fund Management Co. Ltd.’s holdings in Celldex Therapeutics were worth $315,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its position in shares of Celldex Therapeutics by 70.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 805 shares during the period. Strs Ohio lifted its stake in Celldex Therapeutics by 92.9% during the fourth quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 1,300 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Celldex Therapeutics by 36.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,582 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 1,746 shares during the period. Panoramic Investment Advisors LLC purchased a new stake in shares of Celldex Therapeutics during the fourth quarter worth $258,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Celldex Therapeutics during the fourth quarter worth $288,000.

Celldex Therapeutics Trading Down 0.4 %

NASDAQ:CLDX traded down $0.15 during trading hours on Thursday, hitting $41.06. The company’s stock had a trading volume of 445,535 shares, compared to its average volume of 848,837. The stock has a market capitalization of $2.30 billion, a P/E ratio of -14.11 and a beta of 1.60. The stock has a fifty day moving average of $41.71 and a 200-day moving average of $37.03. Celldex Therapeutics, Inc. has a 52-week low of $22.11 and a 52-week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The firm had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million. On average, sell-side analysts forecast that Celldex Therapeutics, Inc. will post -2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

CLDX has been the topic of a number of recent research reports. Guggenheim upped their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $66.00.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.